2-(4-Methylmorpholin-4-ium-4-yl)acetic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-(4-Methylmorpholin-4-ium-4-yl)acetic acid
• 化学式: C7H14NO3+
• 分子量: 160.19
• InChiKey: FTIFGDPEGPMDCA-UHFFFAOYSA-O

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• METHOD FOR PREPARING MEROPENEM USING ZINC POWDER
  申请人：Song Yoon Seok

  公开号：US20120065392A1

  公开（公告）日：2012-03-15

  The present invention relates to an improved method for synthesizing meropenem trihydrate [(1R,5S,6S)-2-[((2′S,4′S)-2′-dimethylaminocarbozyl)pyrrolidin-4′-ylthio]-6-[(R)-1-hydroxyethyl]-1-methylcarbapen-2-em-3-carboxylic acid, trihydrate], which is a novel carbapenem antibiotic.

  本发明涉及一种改进的合成美罗培南三水合物[(1R,5S,6S)-2-[((2'S,4'S)-2'-二甲基氨基甲酰基)吡咯烷-4'-基硫]-6-[(R)-1-羟乙基]-1-甲基碳青霉烯-2-亚胺-3-羧酸，三水合物]的方法，这是一种新型的碳青霉烯类抗生素。
• Process for the production of 3-methylthiopropanal
  申请人：Adisseo France S.A.S.

  公开号：EP1413573A1

  公开（公告）日：2004-04-28

  Process for the Production of 3-methylthiopropanal. A process for the production of 3-methylthiopropanal which reacting reaction medium comprising methyl mercaptan and acrolein in the presence of a catalyst comprising an organic base characterised in that the organic base is a N-alkyl morpholine compound.

  生产3-甲基硫代丙醛的方法。一种生产3-甲基硫代丙醛的方法，其中在存在包括甲硫醇和丙烯醛的反应介质的情况下，通过在有机碱的催化剂存在下反应，所述有机碱为N-烷基吗啉化合物。
• Thiol derivative, metallo-beta-lactamase inhibitors
  申请人：——

  公开号：US20020019543A1

  公开（公告）日：2002-02-14

  Ar is optionally substituted with 1 to 3 R X groups, and where n is 0, 1, 2 or 3; and a group of formula III: 1 herein: R 4 is selected from hydrogen; and straight or branched alkyl; R 5 is selected from hydrogen; straight, branched, unsaturated or alicyclic alkyl, optionally substituted with 1 to 3 R X groups, where the alkyl group is optionally interrupted by X, where X is selected from O, S, NH and N(COCH 3 ); allyloxy and 9-fluorenylmethyloxy; and (CH 2 ) n Ar, where Ar is selected from phenyl, furanyl, thienyl, pyridyl, naphthyl, biphenyl, dibenzofuranyl, dibenzothienyl, fluorenyl and fluorenonyl, where n is 0, 1, 2 or 3, and where Ar is optionally substituted with 1 to 3 R X groups; and R X is selected from OR, CN, C(O)NH 2 , C(O)NHR, C(O)N(R) 2 , OC(O)NH 2 , OC(O)R, CHO, SO 2 NH 2 , SOR, CF 3 , C(O)R, COOR, F, Cl, Br, I, OCH 2 Ph, NHR, N(R) 2 ,, NHCOR, NHCO 2 t-Bu, NHCO 2 allyl, NH 2 , and R, where R is hydrogen, C 1 to C 15 alkyl, or aryl. The invention is further directed to a pharmaceutical composition containing the compound, as well as a method for treating bacterial infections in animals or humans, wherein the composition can be administered in combination with a &bgr;-lactam antibiotic.

  Ar 可以用 1 至 3 个 RX 群取代，其中 n 为 0、1、2 或 3；以及公式 III:1 中的一组，其中：R4 选自氢；直链或支链烷基；R5 选自氢、直链、支链、不饱和或脂环烷基，可选地取代 1 至 3 个 RX 群，其中烷基可以被 X 所打断，X 选自 O、S、NH 和 N(COCH3)；烯丙氧基和 9-芴甲氧基；以及 (CH2)nAr，其中 Ar 选自苯基、呋喃基、噻吩基、吡啶基、萘基、联苯基、二苯并呋喃基、二苯并噻吩基、芴基和芴烯基，其中 n 为 0、1、2 或 3，且 Ar 可选地取代 1 至 3 个 RX 群；而 RX 选自 OR、CN、C(O)NH2、C(O)NHR、C(O)N(R)2、OC(O)NH2、OC(O)R、CHO、SO2NH2、SOR、CF3、C(O)R、COOR、F、Cl、Br、I、O Ph、NHR、N(R)2、NHCOR、NHCO2t-Bu、NHCO2allyl、NH2 和 R，其中 R 是氢、C1 至 C15 烷基或芳基。本发明还涉及一种含有该化合物的药物组合物，以及一种用于治疗动物或人体细菌感染的方法，其中该组合物可以与β-内酰胺类抗生素联合使用。
• Poly(ADP-ribose) polymerase 1 inhibitors structurally unrelated to NAD
  申请人：Institute for Cancer Research

  公开号：US10550108B2

  公开（公告）日：2020-02-04

  Compounds that are not related to NAD, and which target PARP1-histone H4 interaction are provided, as well as compositions of these compounds, and methods for specific inhibition of poly(ADP-ribose) polymerase 1 (PARP-1) using these compounds are provided. These PARP-1 inhibitors may be used to treat cancer in which PARP-1 activation or biologic activity plays a role, including prostate cancer, breast cancer, kidney cancer, ovarian cancer, lymphoma, leukemia, and glioblastoma, among others.

  本研究提供了与 NAD 无关的、针对 PARP1-组蛋白 H4 相互作用的化合物以及这些化合物的组合物，并提供了使用这些化合物特异性抑制聚（ADP-核糖）聚合酶 1（PARP-1）的方法。这些 PARP-1 抑制剂可用于治疗 PARP-1 活化或生物活性起作用的癌症，包括前列腺癌、乳腺癌、肾癌、卵巢癌、淋巴瘤、白血病和胶质母细胞瘤等。
• IMPROVED METHOD FOR PREPARING MEROPENEM USING ZINC POWDER
  申请人：DAEWOONG PHARMACEUTICAL CO., LTD.

  公开号：EP2407468B1

  公开（公告）日：2014-04-16